Asthma – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of asthma for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s asthma forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of asthma?
• Of all people diagnosed with asthma, how many in each country across the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of asthma over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 10 asthma patient populations, as follows:

• Diagnosed 12-month prevalent cases.
• Diagnosed symptomatic 12-month prevalent cases.
• Diagnosed medically controlled 12-month prevalent cases.
• Diagnosed intermittent / mild 12-month prevalent cases.
• Diagnosed moderate / severe 12-month prevalent cases.
• Diagnosed 12-month prevalent cases with eosinophilia.
• Diagnosed 12-month prevalent cases with a history of atopy.
• Diagnosed intermittent / mild drug-treated 12-month prevalent cases.
• Diagnosed moderate / severe drug-treated 12-month prevalent cases.
• Diagnosed drug-treated 12-month prevalent cases.

Note: Coverage may vary by country.